The Aenova Group, a contract manufacturer and development service provider for the pharmaceutical and healthcare industry, is installing four high-speed packaging lines at a cost of around €10 million, as well as an additional bulk production line for large-volume preparations at a cost of €10 million.

In a statement, the company said that the market demand for conventional oral solids tablets, film-coated tablets, and hard capsules is constantly increasing. Extensive expansion projects have already been completed at the Aenova site in Tittmoning. A new production building with a total area of 3,100 square meters was put into operation in 2022.

The investments, including new bulk and packaging lines, amounted to a total of around €35 million and are aimed to increase capacity by 2 to 3 billion packaged tablets in the final expansion stage. The new investment projects which cost around €20 million will increase packaging capacity by around 100 million to a total of 400 million blisters and bulk capacity by almost 1 billion tablets per year.

The first high-speed packaging line will go into operation at the end of 2023, with an almost identical line expected to go into operation in the third quarter of 2024; two further lines will be installed by the first quarter of 2025. A new, fourth production line for large-volume bulk products is to be added by the end of 2024.

“The additional systems in the bulk production area follow the proven principle of semi-continuous production and the new high-performance packaging lines have fully automated end-of-line packaging,” said Helmut Stibich, managing director at the Tittmoning site.  “The higher degree of automation not only brings economic benefits, but also supports our product and service quality. At the same time, the investments will create around 50 new, state-of-the-art jobs in the region.”

“With these investments, Aenova is consistently continuing its growth course and consolidating its leading position among the production facilities for conventional solids in Europe at the Tittmoning site,” said Jan Kengelbach, CEO of the Aenova Group. “This is an important step towards offering our customers delivery times in line with the market and ensuring patient care.”